Thus, Histamine-conjugated-normal human immunoglobulin has a great potential to reduce the excess immune response or hyper-inflammation encountered in diseases like COVID-19 without affecting the ability of the body to clear the virus, especially while specific and selective drugs for down-regulation of NF-κB are not available in current clinical practice. The gene discussed is NFKB1; the disease is COVID-19.